A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma

BACKGROUND: Renal cell carcinoma is one of the most chemoresistant cancers, and its metastatic form requires administration of targeted therapies based on angiogenesis or mTOR inhibitors. Understanding how these treatments impact the human metabolism is essential to predict the host response and adj...

Descripción completa

Detalles Bibliográficos
Autores principales: Jobard, Elodie, Blanc, Ellen, Négrier, Sylvie, Escudier, Bernard, Gravis, Gwenaelle, Chevreau, Christine, Elena-Herrmann, Bénédicte, Trédan, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647878/
https://www.ncbi.nlm.nih.gov/pubmed/26372698
http://dx.doi.org/10.1038/bjc.2015.322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647878/
https://www.ncbi.nlm.nih.gov/pubmed/26372698
http://dx.doi.org/10.1038/bjc.2015.322

Ejemplares similares